Drugs / Recombinant human follicle stimulating hormone (r-hFSH)
Recombinant human follicle stimulating hormone (r-hFSH)
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT01794208 | Jan → Jul 2013 | infertility disorder | Glycotope GmbH | Completed | Missed primary |
| Phase 43 trials | ||||||
| Phase 4 | NCT03755973 | Jan 2020 → May 2023 | endometrial disorder, female infertility | Instituto Valenciano de Infertilidade de Lisboa | Completed | No outcome recorded |
| Phase 4 | NCT01816789 | Mar 2013 → Jul 2016 | — | Andros Day Surgery Clinic | Terminated | No outcome recorded |
| Phase 4 | NCT00829075 | Jan 2005 → Dec 2006 | — | Instituto Valenciano de Infertilidad, IVI VALENCIA | Completed | No outcome recorded |
| Comparator or background therapy8 trials | ||||||
| Phase 2 | NCT01112358 Background | Dec 2005 → Jan 2007 | ovarian hyperstimulation syndrome | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 3 | NCT01509833 Background | Oct 2009 → Mar 2011 | infertility disorder | Royan Institute | Completed | Missed primary |
| Phase 3 | NCT01185704 Background | Nov 2008 → Oct 2011 | polycystic ovary syndrome | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 4 | NCT02046655 Comparator | Jan 2011 → Mar 2014 | infertility disorder | Aristotle University Of Thessaloniki | Completed | Met primary |
| Phase 4 | NCT00844311 Background | Feb 2009 → Jun 2010 | infertility disorder | Rigshospitalet, Denmark | Completed | Met primary |
| Phase 4 | NCT00374634 Comparator | Sep 2006 → Sep 2008 | infertility disorder | Nina la Cour Freiesleben | Completed | No outcome recorded |
| Phase 4 | NCT00298025 Background | Sep 2003 → May 2004 | — | EMD Serono | Completed | No outcome recorded |
| — | NCT00619333 Background | Mar 2007 → Mar 2010 | galactosemia, primary ovarian failure | Maastricht University Medical Center | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant human follicle stimulating hormone (r-hFSH) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01185704 ↗ |
| Known as | follitropin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00619333 ↗ |
| Known as | Follitropin Epsilon | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01794208 ↗ |
| Known as | rFSH | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01816789 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant human follicle stimulating hormone (r-hFSH)” NCT00298025 ↗ |
| Route | Subcutaneous | “Recombinant human follicle stimulating hormone (r-hFSH) will be administered subcutaneously at a dose between 75 and 187.5 international unit (IU) once daily from Day 2 (Day 1...” NCT01185704 ↗ |